NCT00598793 - Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy | Biotech Hunter

Enrollment

242

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

March 31, 2004

Study Completion Date

March 31, 2004

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

biphasic insulin aspart

DRUG

insulin glargine

DRUG

metformin

DRUG

pioglitazone

Trial Locations (27)

14209

Novo Nordisk Investigational Site, Buffalo

17033

Novo Nordisk Investigational Site, Hershey

20186

Novo Nordisk Investigational Site, Warrenton

28803

Novo Nordisk Investigational Site, Asheville

29651

Novo Nordisk Investigational Site, Greer

30067

Novo Nordisk Investigational Site, Marietta

30318

Novo Nordisk Investigational Site, Atlanta

32901

Novo Nordisk Investigational Site, Melbourne

32935

Novo Nordisk Investigational Site, Melbourne

33401

Novo Nordisk Investigational Site, West Palm Beach

43203

Novo Nordisk Investigational Site, Columbus

44708

Novo Nordisk Investigational Site, Canton

60607

Novo Nordisk Investigational Site, Chicago

75230

Novo Nordisk Investigational Site, Dallas

75231

Novo Nordisk Investigational Site, Dallas

75246

Novo Nordisk Investigational Site, Dallas

77030

Novo Nordisk Investigational Site, Houston

78229

Novo Nordisk Investigational Site, San Antonio

79707

Novo Nordisk Investigational Site, Midland

90057

Novo Nordisk Investigational Site, Los Angeles

94520

Novo Nordisk Investigational Site, Concord

94598

Novo Nordisk Investigational Site, Walnut Creek

97504

Novo Nordisk Investigational Site, Medford

98055

Novo Nordisk Investigational Site, Renton

83404-7596

Novo Nordisk Investigational Site, Idaho Falls

40504-2681

Novo Nordisk Investigational Site, Lexington

75390-8858

Novo Nordisk Investigational Site, Dallas